You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Multiplexed Bioassay for Checkpoint Inhibitor Autoimmunity

    SBC: L2 Diagnostics, LLC            Topic: NIAID

    The advent of checkpoint inhibitor (CPI) therapy in human cancer has dramatically changed the landscape of treatment strategies in recent years. Previously, cancers with largely ineffective therapeutics and a poor prognosis, such as melanoma, have experienced significant advances of patients able to extend survival and/or progression free disease. Within the tumor microenvironment, a number of imm ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Drug target identification using CRISPRi/a screening

    SBC: BIOIO, LLC            Topic: 400

    ABSTRACT As phenotypic screening makes a comeback in drug discovery, its major issue is drug target identification. There aren’t good generalizable approaches to do target identification for compounds of interest. Identifying how a new drug works at the molecular level is critical for improving it, which is often needed to give it the best chance of ultimately being both safe and effective in pa ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Multi-Modal Venus Clot Removal Device

    SBC: Caeli Vascular LLC            Topic: NHLBI

    ABSTRACTThis Phase I STTR application from Caeli Vascular, LLC entails a 12-month period focused on the development of a novel endovascular venous thrombectomy device. The PI is a vascular surgeon with biomedical research and entrepreneurship experience, and is supported by a team of highly qualified investigators, including a vascular biologist, neurosurgeon, veterinarian, biomedical engineer, me ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Multi-fold increase in the production of pharmaceutical insulin with Microbial Stem Cell Technology

    SBC: ASIMICA, INC.            Topic: 300

    PROJECT SUMMARY / ABSTRACT The goal of this project is to demonstrate the feasibility of a novel technology that is expected to boost yields from pharmaceutical industrial insulin production by greater than four-fold over conventional methods. Higher yields will lower production costs, generating savings that will ultimately be passed onto the millions of diabetic patients who require daily insuli ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a tool to examine proteomic pathways in the AD brain

    SBC: ProteoWise Inc.            Topic: NIA

    Abstract For the extent of our careers as Alzheimer’s researchers, we have struggled with the limitations imposed by the standard techniques for protein analysis. Western blot, the go-to protein technology of the bench researcher, is no match for the complex brain protein distortions of AD. To remedy this debility, we devised a technology that we are making available to all researchers through t ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Developing Real-time Interaction and Motion Tracking in Immersive Virtual Reality for Telerehabilitation

    SBC: Move LLC            Topic: 102

    Abstract Unceasing breakthroughs in technology will shape future healthcare diagnosis, treatment, and delivery. Telerehabilitation delivers rehabilitative healthcare remotely to overcome spatial, temporal and economic barriers. Effectiveness of telerehabilitation has been seen for patients with orthopedic and traumatic injuries, degenerative central nervous system disorders, and cardiovascular dis ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a New Treatment for Diabetic Wounds

    SBC: NUTRIWYO LLC            Topic: NIDDK

    Abstract: Non-healing wounds affect ~25% of people with diabetes and represent a primary cause of amputation of lower limbs, which is an enormous clinical problem and a substantial economic burden. Given the lack of approved agents that effectively aid in the healing of diabetic wounds, a major need exists for developing novel pharmacological agents for treating diabetic wounds. Chronic diabetic w ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Vaccination against Zika virus infection using mosquito NeSt1 protein

    SBC: L2 Diagnostics, LLC            Topic: NIAID

    Arthropod-borne viruses (arboviruses) present a substantial threat to human and animal health worldwide. They are transmitted by hematophagous arthropods, in which mosquitoes are one of the main transmitters. The mosquito specie, Aedes aegypti, is the primary mosquito vector of several widely spread arboviruses as zika, dengue or West Nile viruses. Mosquitoes transmit these pathogens by inoculatin ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Novel insulin-sensitizing NASH/diabetes drugs.

    SBC: BIOIO, LLC            Topic: 300

    Obesity is associated with an increased risk of a number of chronic and progressive diseases and obesity- related metabolic diseases constitute a significant public health burden. The increased likelihood of developing insulin resistance and diabetes is probably the most commonly recognized risk of being obese. In addition, obesity is also associated with accumulation of lipid in the liver parench ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  10. A Deep Learning Model to Improve Pathologist Interpretation of Donor Kidney Biopsies

    SBC: PlatformSTL (DBA for NewVentureIQ LLC)            Topic: 400

    ABSTRACT More people die every year from kidney disease than breast or prostate cancer. Kidney transplantation is life-saving, yet the donor organ shortage and high organ discard rate contributes to 13 deaths daily among patients awaiting transplant. The decision to use or discard a donor kidney relies heavily on microscopic quantitation of chronic damage by pathologists. The current standard of c ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government